Novavax Inc (NVAX)
9.18
+0.22
(+2.46%)
USD |
NASDAQ |
Nov 07, 16:00
9.16
-0.02
(-0.22%)
After-Hours: 20:00
Novavax Revenue (Annual): 556.38M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 556.38M |
| December 31, 2022 | 1.599B |
| December 31, 2021 | 197.58M |
| December 31, 2020 | 22.39M |
| December 31, 2019 | 18.66M |
| December 31, 2018 | 34.29M |
| December 31, 2017 | 31.18M |
| December 31, 2016 | 15.35M |
| December 31, 2015 | 36.25M |
| December 31, 2014 | 30.66M |
| December 31, 2013 | 20.92M |
| December 31, 2012 | 22.08M |
| December 31, 2011 | 14.69M |
| December 31, 2010 | 0.343M |
| Date | Value |
|---|---|
| December 31, 2009 | 0.325M |
| December 31, 2008 | 1.064M |
| December 31, 2007 | 1.513M |
| December 31, 2006 | 1.738M |
| December 31, 2005 | 5.343M |
| December 31, 2004 | 8.26M |
| December 31, 2003 | 11.78M |
| December 31, 2002 | 15.00M |
| December 31, 2001 | 24.07M |
| December 31, 2000 | 2.475M |
| December 31, 1999 | 1.20M |
| December 31, 1998 | 0.70M |
| December 31, 1997 | 0.50M |
| December 31, 1996 | 0.10M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
18.66M
Minimum
2019
1.599B
Maximum
2022
478.79M
Average
197.58M
Median
2021
Revenue (Annual) Benchmarks
| Pfizer Inc | 58.50B |
| Moderna Inc | 6.754B |
| BioCryst Pharmaceuticals Inc | 331.41M |
| Eli Lilly and Co | 34.12B |
| AIM ImmunoTech Inc | 0.202M |